Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia
Yıl: 2020 Cilt: 9 Sayı: 3 Sayfa Aralığı: 530 - 534 Metin Dili: Almanca DOI: 10.5455/medscience.2019.09.9245 İndeks Tarihi: 21-10-2020
Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia
Öz: Disruption of the E cadherin mediated complex due to loss or depletion of E cadherin results in epithelial abnormalities and serious developmental impairment in varioustissues and organs. The present study aims to determine E cadherin and β catenin expression in patients diagnosed with benign prostatic hyperplasia (BPH) and prostatecarcinoma (PCa) based on Gleason scores and investigate the association of these proteins with PSA levels and Gleason scoring. Immunohistochemical staining for Ecadherin and β catenin was performed in 59 patients diagnosed with PCa and 30 patients with BPH. Mean E cadherin expression was 3.00 in patients diagnosed with BPHand 2.38±0.5 in patients with PCa, with a statistically significant difference between these values (p<0.001). Comparison of PCa cases with PSA <10 versus those withPSA ≥10 revealed significantly reduced β catenin expression in the group with PSA levels ≥10 (p<0.001). Loss of E cadherin and β catenin is known to contribute to thepathogenesis of PCa. We believe that future molecular studies on this subject may further elucidate the association between carcinoma development and the expression ofthese molecules, leading to new therapeutic targets in the treatment of PCa.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
- 2. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. EAU, Arnhem, The Netherlands; 2018. https://uroweb.org/ wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-ProstateCancer-large-text-V2.pdf
- 3. Tinay İ, Akgül HM, Tanıdır Y. Metabolik Sendrom ve Benign Prostat Hiperplazisi: Güncelleme. Üroonkoloji Bülteni. 2014;13:206-9.
- 4. Akgül M, Üren N, Yaman A, Baykan Ö, et al. The Relationship Between Vitamine D Gene Polymorphysms and the Diagnosis of Prostate Cancer at Patients with High PSA Value. Bulletin of Urooncology. 2020.
- 5. Silva RS, Lombardi AP, Souza DS, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. International Journal of Biochemistry and Cell Biology. 2018;96:40–50.
- 6. Musalam A, Andarawi M, Osman M, et al. Alterations of COX-2, HER-2/ neu and E-Cadherin protein expression in the prostatic adenocarcinoma: preliminary findings. Am J Transl Res. 2019;11:1653-67.
- 7. Olson A, Le V, Aldah J, et al. The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression. PLoS Genet. 2019;15:e1008451.
- 8. Abdallah RA, Abdou AG, Abdelwahed M, et al. Immunohistochemical Expression of E‑ and N‑Cadherin in Nodular Prostatic Hyperplasia and Prostatic Carcinoma. J Microsc Ultrastruct. 2019;7:19-27.
- 9. Jaggi M, Johansson SL, Baker JJ, et al. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol. Oncol. Semin. Orig. Investig. 2005;23:402–6
- 10. Kypta R, Waxman J. Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9,418–28.
- 11. Jaggi M, Johansson SL, Baker JJ, et al. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol. Oncol. Semin. Orig. Investig. 2005;23:402–6.
- 12. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837–51.
- 13. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997;275:1784–7.
- 14. Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer. 2004;101:1345–56.
- 15. Lean FZX, Kontos S, Palmieri C. Expression of β-catenin and mesenchymal markers in canine prostatic hyperplasia and carcinoma. J Comp Pathol. 2014;150.373–81.
- 16. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151–66.
- 17. Chunthapong J, Seftor EA, Khalkhali-Ellis Z, et al. Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem. 2004;91;649-61.
- 18. Toivanen R, Mohan A, Shen MM. Basal Progenitors Contribute to Repair of the Prostate Epithelium Following Induced Luminal Anoikis. Stem Cell Reports. 2016;6:660–7.
- 19. Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58:4086–9.
- 20. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.
- 21. Arenas MI, Romo E, Royuela M, et al. N and P cadherin, and alpha, beta and gammacatenin protein expression in normal, hyperplastic and carcinomatous human prostate. Histochem J. 2000;32(:659-67.
- 22. Kobayashi PE, Fonseca-Alves CE, Rivera-Calderón LG, et al. Deregulation of E-cadherin, β-catenin, APC and Caveolin-1 expression occurs in canine prostate cancer and metastatic processes. Res Vet Sci. 2018;118:254-61.
- 23. Koksal IT, Ozcan F, Kilicaslan I, et al. Expression of E-Cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: correlation with pathological features. Pathology. 2002;34:233-8.
- 24. Akgül M, Garayev A, Tinay İ. Active surveillance in prostate cancer: can we expand the indications? Bulletin of Urooncology. 2016;15:163-6.
| APA | İsal Arslan A, karabağ s, AKGÜL M, Yıldırım İ (2020). Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. , 530 - 534. 10.5455/medscience.2019.09.9245 |
| Chicago | İsal Arslan Ayşegül,karabağ sevil,AKGÜL MURAT,Yıldırım İlker Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. (2020): 530 - 534. 10.5455/medscience.2019.09.9245 |
| MLA | İsal Arslan Ayşegül,karabağ sevil,AKGÜL MURAT,Yıldırım İlker Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. , 2020, ss.530 - 534. 10.5455/medscience.2019.09.9245 |
| AMA | İsal Arslan A,karabağ s,AKGÜL M,Yıldırım İ Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. . 2020; 530 - 534. 10.5455/medscience.2019.09.9245 |
| Vancouver | İsal Arslan A,karabağ s,AKGÜL M,Yıldırım İ Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. . 2020; 530 - 534. 10.5455/medscience.2019.09.9245 |
| IEEE | İsal Arslan A,karabağ s,AKGÜL M,Yıldırım İ "Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia." , ss.530 - 534, 2020. 10.5455/medscience.2019.09.9245 |
| ISNAD | İsal Arslan, Ayşegül vd. "Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia". (2020), 530-534. https://doi.org/10.5455/medscience.2019.09.9245 |
| APA | İsal Arslan A, karabağ s, AKGÜL M, Yıldırım İ (2020). Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. Medicine Science, 9(3), 530 - 534. 10.5455/medscience.2019.09.9245 |
| Chicago | İsal Arslan Ayşegül,karabağ sevil,AKGÜL MURAT,Yıldırım İlker Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. Medicine Science 9, no.3 (2020): 530 - 534. 10.5455/medscience.2019.09.9245 |
| MLA | İsal Arslan Ayşegül,karabağ sevil,AKGÜL MURAT,Yıldırım İlker Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. Medicine Science, vol.9, no.3, 2020, ss.530 - 534. 10.5455/medscience.2019.09.9245 |
| AMA | İsal Arslan A,karabağ s,AKGÜL M,Yıldırım İ Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. Medicine Science. 2020; 9(3): 530 - 534. 10.5455/medscience.2019.09.9245 |
| Vancouver | İsal Arslan A,karabağ s,AKGÜL M,Yıldırım İ Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. Medicine Science. 2020; 9(3): 530 - 534. 10.5455/medscience.2019.09.9245 |
| IEEE | İsal Arslan A,karabağ s,AKGÜL M,Yıldırım İ "Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia." Medicine Science, 9, ss.530 - 534, 2020. 10.5455/medscience.2019.09.9245 |
| ISNAD | İsal Arslan, Ayşegül vd. "Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia". Medicine Science 9/3 (2020), 530-534. https://doi.org/10.5455/medscience.2019.09.9245 |
